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ABSTRACT
Background: Birch pollen is the major allergen in pollinosis in northern Japan. IgE reactivity to individual birch
pollen allergens has been shown to differ between populations of birch pollen-allergic patients living in different
countries. In this study, we examined the IgE profiles to recombinant birch pollen allergens in birch-sensitive
patients living in Sapporo.
Methods: This study used the sera of 40 patients with specific IgE toward birch pollen extract. Their sera were
analyzed for specific IgE reactivity to individual birch pollen allergens (recombinant Bet v 1, Bet v 2 and Bet v 4)
and natural birch pollen extract using Pharmacia CAP SystemTM.
Results: Of 40 sera with positive CAP results for natural birch pollen extract, 39 (97.5%) had specific IgE to-
wards Bet v 1; 6 (15%) contained specific IgE against Bet v 2. Bet v 4 reactivity was documented in only one
subject (2.5%).
Conclusions: The present data suggest that the specific IgE reactivity profiles to birch pollen allergen in
birch-sensitive patients in Sapporo correspond to those in Scandinavia, possibly due to the heavy birch pollen
exposure in this area. This observation provides useful information for future birch allergen-specific immuno-
therapy in Japan.
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INTRODUCTION
The major birch pollen allergen, Bet v 1, was first re-
ported in 1989.1 Other relevant birch pollen allergens
are Bet v 22 and Bet v 4.3,4 All these birch pollen aller-
gens are commercially available as diagnostics. There
have been some reports concerning the positive rate
of the specific IgE against these birch allergens in
Europe,5,6 and IgE reactivity to individual birch pollen
allergens has been shown to differ between popula-
tions of birch pollen-allergic patients living in differ-
ent countries.5 In the north of Japan, birch pollen is
the major allergen in pollinosis. However, as yet, no
author has presented an analysis of the IgE profiles to
these birch allergens in Japan. In this study, we pre-
sent an analysis of IgE profiles to recombinant birch
pollen allergens for pollinosis patients living in north-
ern Japan using the immunoenzymatic CAP method.
METHODS
This study used the sera of 40 patients with specific
IgE toward birch pollen extract >0.70 kUAl and the
sera of 10 healthy control subjects without any symp-
toms of oral allergy syndrome (OAS) or allergic rhini-
tis. All patients were recruited from outpatients at the
Department of Otolaryngology of Sapporo Medical
University or Yamamoto ENT Clinic in the period be-
tween April and May 2006. All participating patients
provided informed consent. 20 patients reported
symptoms of OAS to pertinent fresh fruits. The other
Allergology International. 2008;57:93-96
ORIGINAL ARTICLE
1Department of Otolaryngology, 3Department of Clinical Labora-
tory Medicine, Sapporo Medical University, School of Medicine
and 2Yamamoto ENT Clinic, Hokkaido, Japan.
Correspondence: Hideaki Shirasaki, MD. Ph.D., Department of
Otolaryngology, Sapporo Medical University, S―1 W―16 Chuo-ku,
Sapporo, Hokkaido 060−8543, Japan.
Email: shira@sapmed.ac.jp
Received 29 May 2007. Accepted for publication 11 October
2007.
2008 Japanese Society of Allergology
DOI: 10.2332allergolint.O-07-502
Shirasaki H et al.
94 Allergology International Vol 57, No1, 2008 www.jsaweb.jp
Table 1 Demographic characteristics of birch-alergic patients and control subjects
Controls
(n＝10)
Patients
without OAS symptoms
(n＝20)
Patients
with OAS symptoms
(n＝20)
6/49/117/13Sex (male/female)
36 (26―45)45 (14―70)  39 (16―72) Age
＜0.355.4 (0.9―25.2)17.7 (1.4―94.4)Specific IgE to birch polen (T3) (kU/L)
Data expressed as median values and range (in brackets).
Table 2 Percentage of birch-alergic patients with IgE reactivity to the recombinant alergens Bet v 1, Bet v 2, and Bet v 4
Controls
(n＝10)
% (n)
Patients with out OAS symptoms
(n＝20)
% (n)
Patients with OAS symptoms
(n＝20)
% (n)
Recombinant alergens
0 (0)95 (19)100 (20)Bet v 1
0 (0)10 (2) 20 (4)Bet v 2
0 (0)5 (1) 0 (0)Bet v 4
20 patients had no OAS symptoms. Demographic and
clinical characteristics of the patients and controls are
summarized in Table 1.
IgE-specific antibodies for birch (t3), grass (g3),
mugwort (w6), house dust mite (d1) and the recom-
binant birch pollen allergens (rBet v 1, rBet v 2 and
rBet v 4) were evaluated using the immunoenzymatic
CAP method (Pharmacia Diagnosis, Uppsala, Swe-
den) according to the manufacturer’s instructions.
The cutoff value of the assay was 0.35 kUAl.
Spearman correlation coefficients were used to
evaluate whether the serum levels of IgE to natural
birch pollen extract and the IgE levels to recombi-
nant Bet v 1 or Bet v 2 were correlated. Frequency
analysis to evaluate specific IgE positivity to mite,
grass and mugwort among Bet v 2 IgE positive or
negative birch pollen-allergic patients was performed
with Fisher’s exact tests.
RESULTS
Of 40 sera with positive CAP results for natural birch
pollen extract, 39 (97.5%) had specific IgE towards
Bet v 1; 6 (15%) contained specific IgE against Bet
v 2. Bet v 4 reactivity was documented in only one
subject (2.5%) (Table 2). On the other hand, control
subjects were negative for all of the birch-pollen aller-
gens tested. There was no significant difference in
IgE positivity to these birch allergens between pa-
tients with OAS and patients without OAS.
As shown in Figure 1, there was a strong correla-
tion between the serum levels of IgE to natural birch
pollen extract and the IgE levels to recombinant Bet
v 1 (r = 0.996, p = 1.02 × 10−41). A weak, but signifi-
cant, correlation was observed between the levels of
IgE to birch pollen extract and IgE to Bet v 2 (r =
0.536, p = 0.0036) (Fig. 2). No statistical correlation
was found between IgE to birch pollen extract and
IgE to Bet v 4 (r = −0.022, p = 0.676).
In Bet v 2 IgE positive versus negative birch pollen-
allergic patients, there was a significantly higher fre-
quency of positive specific IgE antibodies to mite (6
of 6 vs.18 of 34, p = 0.035), grass (5 of 6 vs. 10 of 34,
p = 0.021) and mugwort (5 of 6 vs. 5 of 34, p = 0.0020)
(Table 3).
DISCUSSION
In the present study, we analyzed the IgE-reactivity
profile among birch pollen-allergic patients in the
northern part of Japan. There was a correlation be-
tween the serum levels of IgE to natural birch pollen
extract and IgE levels to recombinant Bet v 1. While
IgE antibodies to Bet v 1 were almost certainly pre-
sent in patients from Sweden, Finland and Austria (
98) and common in France (90%), they were present
in less than 70% of patients from Switzerland and
northern Italy.5 In contrast, IgE reactivity to Bet v 2
was rare in Scandinavian patients, while it was more
abundant in patients living in central or southern
Europe.5,6 Thus, the present data suggest that the
specificities of IgE reactivity profiles in relation to
birch pollen allergen in Japanese birch-allergic pa-
tients correspond to those in Scandinavian patients,
which differ from results obtained in patients from
northern Italy.5,6 Rossi et al. suggested that Bet v 2
reactivity in the patients from the northern Italy
might indicate that these subjects have primarily
been sensitized to allergens from other sources, such
as grass pollen.6 In Sapporo, only birch pollen con-
centrations are high,7 suggesting that birch-allergic
patients in Sapporo have primarily been sensitized to
birch pollen allergen. To prove this hypothesis, a
comparison of IgE profiles in the sera of birch pollen-
sensitive patients in an area of lower exposure to
birch pollen will be necessary.
Bet v 4 has been reported to be a calcium binding
protein of birch pollen allergen.4 Only 2.5% of patients
with specific IgE towards birch pollen extract had se-
rum IgE specific to Bet v 4 in the present study. This
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Table 3 Percentage of birch-alergic patients with IgE re-
activity to other major alergens
p value
Bet v 2 negative
(n＝34)
% (n)
Bet v 2 positive
(n＝6)
% (n)
Alergen
0.035 53 (18)100 (6)Mite
0.021 29 (10) 83 (5)Grass
0.002015 (5)  83 (5)Mugwort
Fig. 1 Significant corelation between specific IgE levels to 
recombinant Bet v 1 and specific IgE levels to birch polen 
extract (T3). (p＝1.02×10－41)
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Fig. 2 A weak, but significant corelation between specific
IgE levels to recombinant Bet v 2 and specific IgE levels to
birch polen extract (T3). (p＝0.0036)
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observation is similar to that in a previous report in
European populations regarding sensitivity to Bet
v 4.5,6 Moreover, there was no significant statistical
correlation between IgE specificity to birch pollen ex-
tract and Bet v 4 in the present study. From these ob-
servations it appears that the clinical significance of
Bet v 4 in birch-allergic patients may be minor.
In this study, we demonstrated that patients with
IgE to Bet v 2 (profilin) frequently have IgE not only
to other pollen but also to house dust mite. Although
the frequency of birch pollen allergy in mugwort-
allergic patients is high,8 as yet, no author has re-
ported a relationship between mite-allergy and birch-
allergy. Profilins are present in almost all eukaryotic
cells and are highly cross-reactive as panallergen.9
Profilins are structurally conserved eukaryotic pro-
teins which have been described as allergens in
trees, grasses, weed pollens, fruits, vegetables, nuts,
latex and even in man.10 Profilin-sensitized patients
may either exhibit clinically relevant reactivity to sev-
eral of the allergen sources or be at risk of develop-
ing allergic symptoms.
The only treatment for IgE-mediated allergy that
leads to long-lasting relief of symptoms is allergen-
specific immunotherapy. According to the arguments
outlined by Kazemi-Shirazi, patients with IgE antibod-
ies specific for Bet v 1 are considered suited for birch
pollen extract-based immunotherapy, and those pa-
tients with specific IgE to Bet v 2 and Bet v 4, but not
to Bet v 1, are not suitable for birch pollen immuno-
therapy.10 However, symptomatic medication is the
most standard therapy for Japanese birch pollen aller-
gic patients because allergen extract used for immu-
notherapy specific to birch pollen has not been per-
mitted in Japan. Recently, the clinical efficacy of spe-
cific immunotherapy using Bet v 1 has been re-
ported.11,12 Our present study of IgE profiles will pro-
vide useful information for future birch allergen-
specific immunotherapy in Japan.
In summary, we have shown that sensitization
solely to Bet v 2 (profilin) is rare among birch pollen-
allergic patients in northern Japan. The majority are
sensitized to birch major allergen Bet v 1, possibly
due to the heavy birch pollen exposure in this area.
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